Second, although we assessed that KLF5 was vital in GBM and bladder cancer progression, the lack of in vivo validation using animal models limits the translation of our in vitro findings to clinical settings, and in-depth mechanisms based on this phenomenon should be conducted and the interaction between KLF5 and tumor microenvironment are crucial to be explored. This evidence concerns the gene KLF5 and urinary bladder cancer.